Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To describe the use and reporting of interrupted time series methods in drug utilization research. STUDY DESIGN AND SETTING: We completed a systematic search of MEDLINE, Web of Science, and reference lists to identify English language articles through to December 2013 that used interrupted time series methods in drug utilization research. We tabulated the number of studies by publication year and summarized methodological detail. RESULTS: We identified 220 eligible empirical applications since 1984. Only 17 (8%) were published before 2000, and 90 (41%) were published since 2010. Segmented regression was the most commonly applied interrupted time series method (67%). Most studies assessed drug policy changes (51%, n = 112); 22% (n = 48) examined the impact of new evidence, 18% (n = 39) examined safety advisories, and 16% (n = 35) examined quality improvement interventions. Autocorrelation was considered in 66% of studies, 31% reported adjusting for seasonality, and 15% accounted for nonstationarity. CONCLUSION: Use of interrupted time series methods in drug utilization research has increased, particularly in recent years. Despite methodological recommendations, there is large variation in reporting of analytic methods. Developing methodological and reporting standards for interrupted time series analysis is important to improve its application in drug utilization research, and we provide recommendations for consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–231 of 231
Simon, S. R., & Soumerai, S. B. (2005) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzi044 · Cited by 20
Foulon, V., Svala, A., Koskinen, H., Chen, T. F., Saastamoinen, L., & Bell, J. S. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0040 · Cited by 19
Atomoxetine Use During a Period of FDA Actions
Du, D., Zhou, E. H., Goldsmith, J. V., Nardinelli, C., & Hammad, T. A. (2012) · Medical Care · doi:10.1097/mlr.0b013e31826c86f1 · Cited by 19
MEASURING THE EFFECT OF POLICY INTERVENTIONS AT THE POPULATION LEVEL: SOME METHODOLOGICAL CONCERNS
Huesch, M. D., Østbye, T., & Ong, M. K. (2011) · Health Economics · doi:10.1002/hec.1783 · Cited by 18
Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia
Marra, F., Patrick, D. M., White, R., Ng, H., Bowie, W., & Hutchinson, J. M. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh501 · Cited by 18
Choudhry, N. K., Zagorski, B., Avorn, J., Levin, R., Sykora, K., Laupacis, A., & Mamdani, M. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l211 · Cited by 18
Self-citationThe Impact in Japan of Regulatory Action on Prescribing of Dopamine Receptor Agonists
Ooba, N., Yamaguchi, T., & Kubota, K. (2011) · Drug Safety · doi:10.2165/11588230-000000000-00000 · Cited by 17
Prescribing of nicotine replacement therapy to cardiovascular disease patients in England
Langley, T. E., Szatkowski, L., McNeill, A. D., Coleman, T. J., & Lewis, S. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03794.x · Cited by 16
Mass media release of medical research results
Brunt, M. E., Murray, M. D., Hui, S. L., Kesterson, J. G., Perkins, A. J., & Tierney, W. M. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.20502.x · Cited by 16
Changes in Cholesterol-Lowering Medications Use Over a Decade in Community-Dwelling Older Adults
Lo-Ciganic, W.-H., Boudreau, R. M., Gray, S. L., Zgibor, J. C., Donohue, J. M., Perera, S., Newman, A. B., Simonsick, E. M., Bauer, D. C., Satterfield, S., et al. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1s050 · Cited by 16
Bennie, M., Bishop, I., Godman, B., Barbui, C., Raschi, E., Campbell, S., Miranda, J., & Gustafsson, L. L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12100 · Cited by 16
Atchessi, N., Ridde, V., & Haddad, S. H. S. (2012) · Health Policy and Planning · doi:10.1093/heapol/czs100 · Cited by 16
Rosiglitazone Prior Authorization Safety Policy: A Cohort Study
Starner, C. I., Fenrick, B., Coleman, J., Wickersham, P. J., & Gleason, P. P. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.3.225 · Cited by 15
Thamer, M., Zhang, Y., Lai, D., Kshirsagar, O. S., & Cotter, D. J. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-172 · Cited by 14
Grégoire, J., Moisan, J., Potvin, L., Chabot, I., Verreault, R., & Milot, A. (2006) · BMC Health Services Research · doi:10.1186/1472-6963-6-33 · Cited by 14
Bijlsma, M. J., Hak, E., Bos, J., den Berg, L. T. W. D. J., & Janssen, F. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3466 · Cited by 13
SKETRIS, I. S., Kephart, G. C., Frail, D. M., Skedgel, C. D., & Allen, M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.8.784.36073 · Cited by 13
Restocking the sample closet: results of a trial to alter medication prescribing.
Mukamal, K. J., Markson, L. J., Flier, S. R., & Calabrese, D. (2002) · PubMed · Cited by 13
Warnings Without Guidance: Patient Responses to an FDA Warning About Ezetimibe
Shrank, W. H., Choudhry, N. K., Tong, A., Myers, J. A., Fischer, M. A., Swanton, K., Slezak, J., Brennan, T. A., Liberman, J. N., Moffit, S., et al. (2012) · Medical Care · doi:10.1097/mlr.0b013e31825517b6 · Cited by 13
Improving cardiovascular disease management in Australia: NPS MedicineWise
Gadzhanova, S., Roughead, E. E., & Bartlett, M. J. (2013) · The Medical Journal of Australia · doi:10.5694/mja12.11779 · Cited by 13
Adnan, W. A. H. W. M., Zaharan, N. L., Bennett, K., & Wall, C. A. M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03835.x · Cited by 11
Kong, M., Cambon, A. C., & Smith, M. J. (2012) · Communication in Statistics- Theory and Methods · doi:10.1080/03610926.2011.563020 · Cited by 11
Damiani, G., Federico, B., Silvestrini, G., et al. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1422-3 · Cited by 11
Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility
Koranek, A., Smith, T. L., Mican, L. M., & Rascati, K. L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.01.043 · Cited by 9
Cortoos, P., Gilissen, C., Mol, P. G. M., den Bossche, F. V., Simoens, S., Willems, L., Leenaers, H., Vandorpe, L., Peetermans, W. E., & Laekeman, G. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr366 · Cited by 8
Lowe, D. O., Lummis, H. L., Zhang, Y., & SKETRIS, I. S. (2008) · PubMed · Cited by 7
The impact of the Women's Health Initiative study on incident clonidine use in Ontario, Canada.
Austin, P. C., Mamdani, M., & Tu, K. (2004) · PubMed · Cited by 7
Self-citationPolinski, J. M., Brookhart, M. A., Glynn, R. J., & Schneeweiß, S. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823fb5c4 · Cited by 6
The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada
Marshall, D. A., Willison, D. J., Grootendorst, P. V., LeLorier, J., Maclure, M., Kulin, N. A., Sheehy, O., Warren, L. D., Sykora, K., & Rahme, E. (2007) · Health Policy · doi:10.1016/j.healthpol.2007.04.010 · Cited by 5
Impact of high dose statin trials on hospital prescribers
Barron, T. I., Bennett, K., & Feely, J. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0208-x · Cited by 4
Cited by
Schaffer, A. L., Dobbins, T. A., & Pearson, S.-A. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01235-8 · Cited by 794
Angoulvant, F., Ouldali, N., Yang, D. D., Filser, M., Gajdos, V., Rybak, A., Guedj, R., Soussan-Banini, V., Basmaci, R., Lefevre-Utile, A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa710 · Cited by 306
Critical care transition programs and the risk of readmission or death after discharge from ICU.
Stelfox, H. T., Bastos, J., Niven, D. J., Bagshaw, S. M., Turin, T. C., & Gao, S. (2016) · Intensive Care Medicine · doi:10.1007/s00134-015-4173-7 · Cited by 60
Cross-sectional studies: strengths, limitations, and methodological considerations
Baumeister, S., Kocher, T., Papapanou, P. N., Holtfreter, B., & Demmer, R. T. (2026) · Journal of Periodontal Research · doi:10.1111/jre.70063 · Cited by 38
Rahemtulla, K. A., Cheema, M. K., Nickonchuk, T., Guirguis, M., Al Hamarneh, Y. N., & Damji, K. F. (2022) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2021.06.005 · Cited by 11
Metadata
- Authors
- Jandoc, R., Burden, A. M., Mamdani, M., Lévesque, L. E., & Cadarette, S. M.
- Venue
- Journal of Clinical Epidemiology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 68
- Issue
- 8
- Pages
- 950-956
- ISSN
- 0895-4356 (ISSN-L)
- OpenAlex
- W2119863846
- Cited by
- 474
- References
- 231
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.